CD19 and Parkinson disease: However, this could have been induced by MSM’s L-DOPA, in line with Hurny et al. (2013), who observed appreciably increased CD16 and CD19 lymphocytes in the peripheral blood of Parkinson disease patients treated with L-DOPA.